Evidence map›Paper›PMID 38420590›Full record

ArticleiScience2024

Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression.

Stephanie L Tzetzo, Elliot D Kramer, Hemn Mohammadpour, Minhyung Kim, Spencer R Rosario, Han Yu, Melissa R Dolan, Chetan C Oturkar, Brian G Morreale, Paul N Bogner and 9 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Stephanie L TzetzoDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Elliot D KramerDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Hemn MohammadpourDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Minhyung KimDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Spencer R RosarioDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Han YuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Melissa R DolanDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Chetan C OturkarDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Brian G MorrealeDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Paul N BognerDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Aimee B StablewskiDepartment of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Fernando J BenavidesDepartment of Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center, Houston, TX 77030, USA.
Craig M BrackettDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
John M L EbosDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Gokul M DasDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Mateusz OpyrchalDepartment of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Michael J NemethDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Sharon S EvansDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Scott I AbramsDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Roswell Park Comprehensive Cancer Center · USIndiana University – Purdue University Indianapolis · USThe University of Texas MD Anderson Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor ImmunityR01CA250412 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., EVANS, SHARON S · 2021 to 2025
$3.4M
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGYT32CA085183 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Scott I. Abrams · 2001 to 2026
$3.1M
Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancerR01CA251545 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAS, GOKUL M. · 2021 to 2025
$2.9M
Mechanisms Underlying Functional Programs of Tumor-Associated MacrophagesR01CA172105 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I. · 2015 to 2019
$2.0M
Development of a Novel Immunotherapy Platform for Triple-Negative Breast CancerR21CA256321 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., BRACKETT, CRAIG M. · 2021 to 2022
$429k
The Wnt-IRF8 axis: a Novel Regulator of Myeloid-Derived Suppressor Cell BiologyF30CA254327 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KRAMER, ELLIOT DAVID · 2020 to 2023
$161k
Transcriptional Control of Macrophage-Mediated Mechanisms of MetastasisF31CA243304 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TZETZO, STEPHANIE · 2019 to 2021
$91k
NCI NIH HHS F30 CA254327NCI NIH HHS F31 CA243304NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA172105NCI NIH HHS R01 CA250412NCI NIH HHS R01 CA251545NCI NIH HHS R21 CA256321NCI NIH HHS T32 CA085183
6 · The paper itself

Abstract

Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic sites, yet their functional contributions to metastasis remain incompletely understood. Here, we show that alveolar macrophages (AMs), the main TRMs of the lung, are susceptible to downregulation of the immune stimulatory transcription factor IRF8, impairing anti-metastatic activity in models of metastatic breast cancer. G-CSF is a key tumor-associated factor (TAF) that acts upon AMs to reduce IRF8 levels and facilitate metastasis. Translational relevance of IRF8 downregulation was observed among macrophage precursors in breast cancer and a

Indexed as

CancerImmunologyMicroenvironment

Identifiers

PMID38420590
PMCPMC10901102
OpenAlexW4391715326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.